Extended Data Fig. 2: Drug sensitivity profiling by CellTiter-Glo cell viability assay.
From: The chemotherapeutic drug CX-5461 is a potent mutagen in cultured human cells
Drug sensitivity profiling of isogenic RPE1-BRCA1−/−, BRCA2−/−, and control cells to CX-5461, topoisomerase II poison, etoposide (ETO), and G-quadruplex stabilising compound, pyridostatin (PDS) confirmed synthetic lethality of CX-5461 in RPE1-BRCA1−/−, BRCA2−/− cells. RPE1-LIG4−/− was used as a positive control. Cells were also profiled against two other therapeutic agents commonly used for the treatment of BRCA1/2-mutated cancers, cisplatin, and olaparib. Data are mean ± standard errors (error bars), n = 3 independent biological replicates. All comparisons were made against WT. Two-tailed Wilcoxon signed-rank test was used to calculate P values.
